ZYME Zymeworks Inc. Net earnings per share growth this year

ZYME (Zymeworks Inc.) - company brandmark

Zymeworks Inc. (ZYME) antibody development relies on partner payments and grants, necessitating strict cost control despite a liquid balance sheet. The year-over-year change in EPS clearly demonstrates a recovery from the crisis, with the current parameter equal to 205.50. Management's strategic course focuses on optimizing oncology projects and securing investments. The business foundation is the Azymetric ecosystem, which connects pharma behemoths through licensing.

Zymeworks (ZYME): Net earnings per share growth this year from 07/04/2022 to 11/11/2026

Analytical breakdowns and data insights for company Zymeworks Inc. (ZYME)

- current quotes and average value forecast:
Market Chart Zymeworks Inc|ZYME - Price Target Chart
- market capitalization data:
Market Valuation Zymeworks Biopharmaceuticals|ZYME - Total Company Value
- company book value details:
Accounting Value per Share Zymeworks|ZYME - Company Net Assets|Market Capitalization to Book Value Ratio zymeworks.com|ZYME - Aggregate Company Assets
- debt and liquidity details:
Debt to Equity Ratio Zymeworks Inc.|ZYME - Long-Term Debt to Equity|Current Liabilities to Capital zymeworks.com|ZYME - Company Total Debt|Debt to Net Assets Zymeworks Biopharmaceuticals|ZYME - Company Long-Term Liabilities|Amount of Current Liabilities Zymeworks|Intermediate Coverage Ratio zymeworks.com
- net income and valuation ratios data:
ZYME - Net Profit|Expected Net Profit Zymeworks Inc.|ZYME - Price to Earnings Ratio|Future Price to Earnings Multiple Zymeworks Biopharmaceuticals|ZYME - PEG Multiple|EV/EBITDA Multiple Zymeworks Biopharmaceuticals|ZYME - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Zymeworks|ZYME - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months zymeworks.com|ZYME - Net earnings per share growth this year|Net earnings per share change forecast for next year Zymeworks Inc.
Summary company analysis:ZYME (Zymeworks Inc)
Brand item of Zymeworks Corp

This indicator reflects the year-over-year earnings per share (EPS) dynamics with daily updates, allowing for the tracking of yield change rates without quarterly lags. The current value of 205.50 on the annual EPS growth trajectory confirms the financial stability of Zymeworks Inc. (ZYME), whose market capitalization is supported by the exclusivity of the Azymetric platform and high barriers to entry in the solid tumor therapy segment.

Key competitors

IBRX - Expected net earnings per share growth this year|Earnings per share growth in current year Immunocore PLC|Net earnings per share growth this year Janux Corp (JANX)|Earnings per share growth in current year Arcus Biosciences, Inc. (RCUS)|Net earnings per share growth this year tangotx.com TNGX|Iovance Biotherapeutics, Inc. - Net earnings per share growth this year|Earnings growth in current year Immatics NV IMTX|XNCR - Earnings per share growth in current year|CMPX (Compass Therapeutics Corp) - Earnings per share growth this year|Replimune Group, Inc. (REPL) - Earnings per share growth in current year|Earnings per share growth rate in current year lyell.com (LYEL)|Net earnings per share growth this year IPHA|PYXS - Net earnings per share change in current year|Net earnings per share growth this year CGEN (Compugen Ltd.)|Net earnings per one share growth for the current year IOBT|Earnings growth in current year STRO (Sutro Biopharma, Inc.)|Earnings per share increase in current year INKT|Werewolf - Earnings growth in current year|Earnings per share growth rate in current year Immix Biopharma, Inc.|ALX Oncology (ALXO) - Earnings per share growth in current year|Cue Biopharma Inc. - Earnings per share increase in current year|PDSB (PDS Biotech) - Earnings growth in current year|Earnings growth in current year Sonnet BioTherapeutics Holdings Inc.|Earnings per share growth in current year MAIA Biotechnology, Inc. (MAIA)|LIMN: Earnings per share trend in current year|LAVA Therapeutics - Net earnings per share growth this year|NextCure Corporation (NXTC) - Earnings per share growth rate in current year|LPTX: Net earnings per share growth this year|Earnings per share trend in current year INTS|SNSE (senseibio.com) - Net earnings per share growth this year|Earnings per share growth rate in current year Theriva Biologics Inc (TOVX)|Earnings per share growth in current year Gritstone bio Inc.|Net earnings per share growth this year Kineta Corp (KA)|Earnings growth in current year NEXI|TSBX - Earnings per share growth rate in current year|Vaccinex - Net earnings per share growth this year|HARP - Net earnings per share growth this year